心臟衰竭即時檢測和遠端檢測設備市場—全球產業規模、佔有率、趨勢、機會和預測：按研究類型、技術、最終用途、地區和競爭格局分類，2021-2031年

全球用於治療心臟衰竭的即時檢測 (POC) 和晶片實驗室 (LOC) 設備的市場預計將從 2025 年的 1.2101 億美元大幅成長到 2031 年的 1.9536 億美元，複合年成長率為 8.31%。

這些診斷平台對於在患者床邊或社區醫療機構直接測量心臟生物標記（例如利鈉肽）至關重要，從而無需中心檢查室處理。這一成長主要受全球心血管疾病發病率上升以及透過高效的患者分流和最佳化治療方案來降低再入院率的迫切需求所驅動。此外，隨著老年人口的增加，人們對便利的、分散式檢查解決方案的需求日益成長，這些方案能夠幫助快速做出臨床決策，並提高患者的用藥依從性，即使在傳統急診機構之外也是如此。然而，阻礙該市場發展的一個主要挑戰是缺乏統一的報銷政策。與現有檢查室方法相比，分散式診斷的單次檢測成本往往更高，而且這些成本通常無法得到充分的報銷。這一經濟障礙尤其顯著，因為美國心臟衰竭協會估計，到2025年，美國將有670萬成年人患有心臟衰竭。這種情況凸顯了對便利且經濟高效的診斷工具的迫切需求。

市場促進因素

微流體和生物感測器技術的顯著進步正在革新心臟衰竭的診斷方式，使得在臨床環境中直接進行高精度心臟生物標記分析成為可能。將高靈敏度檢測整合到攜帶式設備中，使臨床醫生能夠快速檢測到細微的生理變化，從而實現即時分診和治療方案調整。這種診斷準確性的提升對於在緊急情況下快速排除非心臟原因引起的症狀至關重要，避免了傳統檢測帶來的延遲。例如，羅氏診斷公司於2025年9月發布的TSIX研究計畫的關鍵結果表明，該公司第六代高靈敏度肌鈣蛋白T檢測在識別超過13,000名參與者的急性心肌事件方面具有卓越的準確性。此類創新減少了對中心檢查室的依賴，最佳化了臨床工作流程，並縮短了高風險患者獲得有效干預的時間。同時，全球心臟衰竭盛行率的不斷上升是市場擴張的主要驅動力，也使得便捷的監測解決方案的需求日益迫切。隨著心臟衰竭患者人數持續成長，醫療系統正擴大採用分散式檢查來應對日益慢性心臟疾病負擔。英國心臟基金會於2025年5月發布報告稱，英國心臟衰竭確診人數將比2020年激增21%，到2024年達到78.5萬人。此外，美國心臟衰竭協會指出，2022年美國有425,147人死於心臟衰竭，凸顯了早期檢測和管理工具的重要性，這些工具需要能夠有效地處理大量檢測樣本。

市場挑戰

不一致的報銷機制構成了一項重大的經濟障礙，直接阻礙了全球心臟衰竭即時檢測（POC​​）和院內檢測（LOC）設備市場的商業性擴張。儘管這些分散式診斷平台能夠快速提供檢測結果，具有許多營運優勢，但其單位生產成本通常高於傳統的高通量中心檢查室檢測。因此，保險公司和國家醫療保健計劃通常分配的報銷代碼未能充分反映這一成本溢價，而支付給醫療服務提供者的費用往往基於較低的標準檢查室收費標準。這種不平衡對醫院和社區診所造成了財務壓力，因為實施這些先進設備通常會導致每次檢測的營運利潤為負。創新技術的成本與支付方保險覆蓋範圍之間的這種財務錯配迫使醫療機構限制床邊診斷設備的採用，儘管加快病患分診的營運需求十分迫切。心臟衰竭的治療成本巨大，美國心臟衰竭協會報告稱，到2025年，該疾病每年將導致120萬例新增住院病例。鑑於需要緊急護理的病例數量極其龐大，醫療保健提供者無法收回與快速即時檢測 (POC) 相關的某些成本，最終限制了市場滿足對更快、更有效率的診斷解決方案日益成長的需求的能力。

市場趨勢

一個顯著的市場趨勢是居家和分散式病患監測的轉變。這從根本上改變了診斷方式，將診斷直接從急診護理機構轉移到患者家中。穿戴式感測器能夠傳輸即時血流動力學數據，使臨床醫生無需患者親自前往診所即可調整用藥方案，從而實現了這一轉變。與間歇性的醫院檢查不同，持續的生理監測能夠實現預防性干預，並直接滿足降低再入院率這一關鍵需求。例如，2025年5月，心血管血管造影術和介入學會（SCAI）報告稱，利用穿戴式科技的遠端追蹤系統可以將心臟衰竭患者的住院率降低33.1%。同時，人工智慧（AI）在預測分析中的應用顯著提高了即時檢測設備的性能，將原始感測器數據轉化為可操作的診斷資訊。製造商正在將機器學習演算法整合到攜帶式讀取器中，以識別通常領先臨床惡化出現的複雜生物標記模式，從而將診斷的重點從簡單的檢測轉移到主動的風險預測。即使在無法立即獲得專家診斷的非產房環境中，這項功能也能顯著提高診斷的可靠性。根據 News-Medical.Net 於 2025 年 11 月報道，一款新型人工智慧數位聽診器在檢測心臟疾病方面展現出超過 90% 的靈敏度和特異性，遠超傳統聽診方法。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章 全球心臟衰竭即時檢測與遠端檢測設備市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 檢測類型（蛋白質體學檢測、代謝體學學檢測、基因體學檢測）
  • 依技術分類（微流體、陣列式系統等）
  • 透過應用（診所、醫院、家庭護理、輔助生活設施、檢查室等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美心臟衰竭即時偵測與遠端偵測設備市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲心臟衰竭即時偵測與遠端偵測設備市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區心臟衰竭即時檢測與遠端檢測設備市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲心臟衰竭即時偵測和遠端偵測設備的市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲心臟衰竭即時偵測與遠端偵測設備市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球心臟衰竭即時偵測與遠端偵測設備市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Abbott Laboratories Inc
• Siemens Healthineers AG
• Danaher Corp
• Instrumentation Laboratory Co
• F Hoffmann-La Roche AG
• bioMerieux SA
• Abaxis Inc
• Quidel Corp
• Jant Pharmacal Corp
• Trinity Biotech plc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Heart Failure Point-of-Care (POC) and Lab-on-Chip (LOC) Devices Market is projected to expand significantly, growing from USD 121.01 million in 2025 to USD 195.36 million by 2031, at a Compound Annual Growth Rate (CAGR) of 8.31%. These diagnostic platforms are crucial for measuring cardiac biomarkers like natriuretic peptides directly at a patient's bedside or in community settings, eliminating the need for central laboratory processing. This growth is primarily fueled by the increasing worldwide incidence of cardiovascular diseases and the urgent requirement to decrease hospital readmission rates through efficient patient triage and optimized treatment plans. Furthermore, the rising number of elderly individuals necessitates readily available, decentralized testing solutions that facilitate prompt clinical decision-making and enhance patient adherence outside of traditional acute care facilities. However, a key challenge impeding this market's potential is the lack of consistent reimbursement policies, which often fail to adequately cover the higher per-test expenses of decentralized diagnostics compared to established laboratory methods. This financial hurdle is particularly impactful given that an estimated 6.7 million adults in the United States were living with heart failure in 2025, according to the Heart Failure Society of America, highlighting the critical demand for accessible yet cost-effective diagnostic tools.

Market Driver

Significant advancements in microfluidics and biosensor technology are profoundly transforming heart failure diagnostics by enabling highly precise cardiac biomarker analysis directly at the point of care. The incorporation of sensitive assays into portable devices allows clinicians to swiftly detect subtle physiological changes, facilitating immediate triage and treatment adjustments. This enhanced diagnostic accuracy is vital for quickly ruling out non-cardiac causes of symptoms in emergency situations, thereby avoiding delays associated with conventional testing. For instance, primary results from Roche Diagnostics' 'TSIX Study Program' in September 2025 showcased the exceptional precision of their sixth-generation high-sensitivity Troponin T test in identifying acute myocardial events among over 13,000 participants. Such innovations reduce dependence on central laboratories, optimize clinical workflows, and shorten the time to effective intervention for high-risk patients. Concurrently, the escalating global prevalence of heart failure serves as a primary driver for market expansion, generating an urgent need for accessible monitoring solutions. As the number of heart failure patients continues to climb, healthcare systems are increasingly adopting decentralized testing to manage the growing burden of chronic cardiac conditions. The British Heart Foundation reported in May 2025 that the number of individuals diagnosed with heart failure in the UK surged by 21% from 2020 to reach 785,000 in 2024. Additionally, the Heart Failure Society of America noted that heart failure contributed to 425,147 deaths in the United States in 2022, underscoring the critical importance of early detection and management tools capable of handling high testing volumes efficiently.

Market Challenge

Inconsistent reimbursement frameworks pose a significant economic barrier that directly hampers the commercial expansion of the Global Heart Failure POC and LOC Devices Market. Despite the operational advantages of rapid results offered by these decentralized diagnostic platforms, their per-unit production costs are generally higher than those of traditional, high-throughput central laboratory assays. Consequently, insurance providers and national healthcare systems often allocate reimbursement codes that do not adequately reflect this cost premium, frequently compensating providers at the lower standard laboratory rate. This disparity creates a financial disincentive for hospitals and community clinics, as adopting these advanced devices often results in a negative operating margin per test performed. This financial misalignment between the cost of innovative technology and payer coverage compels healthcare facilities to limit their acquisition of bedside diagnostics, even though there is an urgent operational need for faster patient triage. The financial implications of managing heart failure are substantial, with the Heart Failure Society of America reporting in 2025 that the condition accounted for 1.2 million primary hospitalizations annually. Given this high volume of acute care episodes, the inability of healthcare providers to recoup the specific costs associated with rapid POC testing ultimately restricts the market's capacity to meet the growing demand for quicker, more efficient diagnostic solutions.

Market Trends

A notable market trend involves the shift toward home-based and decentralized patient monitoring, which is fundamentally changing how diagnostics are conducted by moving them from acute care settings directly into patients' homes. This transition is made possible by wearable sensors that transmit real-time hemodynamic data, enabling clinicians to adjust medication regimens without requiring in-person office visits. Unlike intermittent, hospital-based testing, continuous physiological monitoring facilitates proactive intervention, directly addressing the critical need to reduce hospital readmission burdens. For example, the Society for Cardiovascular Angiography & Interventions reported in May 2025 that remote tracking systems leveraging wearable technology led to a 33.1% reduction in hospitalizations for heart failure patients. Simultaneously, the integration of Artificial Intelligence (AI) for predictive analytics is significantly enhancing point-of-care devices by converting raw sensor data into actionable diagnostic insights. Manufacturers are embedding machine learning algorithms into portable readers to identify complex biomarker patterns that often precede clinical decompensation, thus shifting the diagnostic focus from mere detection to proactive risk forecasting. This capability substantially boosts diagnostic confidence in non-laboratory environments, where expert interpretation might not be immediately available. As highlighted by News-Medical.Net in November 2025, a new AI-enabled digital stethoscope demonstrated over 90% sensitivity and specificity in detecting heart conditions, markedly outperforming traditional auscultation methods.

Key Market Players

• Abbott Laboratories Inc
• Siemens Healthineers AG
• Danaher Corp
• Instrumentation Laboratory Co
• F Hoffmann-La Roche AG
• bioMerieux S.A.
• Abaxis Inc
• Quidel Corp
• Jant Pharmacal Corp
• Trinity Biotech plc

Report Scope

In this report, the Global Heart Failure POC And LOC Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Heart Failure POC And LOC Devices Market, By Test Type

• Proteomic testing
• Metabolomic testing
• Genomic testing

Heart Failure POC And LOC Devices Market, By Technology

• Microfluidics
• Array-based systems
• Others

Heart Failure POC And LOC Devices Market, By End Use

• Clinics
• Hospitals
• Home
• Assisted living healthcare facilities
• Laboratory
• Others

Heart Failure POC And LOC Devices Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heart Failure POC And LOC Devices Market.

Available Customizations:

Global Heart Failure POC And LOC Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Heart Failure POC And LOC Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Proteomic testing, Metabolomic testing, Genomic testing)
  • 5.2.2. By Technology (Microfluidics, Array-based systems, Others)
  • 5.2.3. By End Use (Clinics, Hospitals, Home, Assisted living healthcare facilities, Laboratory, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Heart Failure POC And LOC Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Heart Failure POC And LOC Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Heart Failure POC And LOC Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Heart Failure POC And LOC Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By End Use

7. Europe Heart Failure POC And LOC Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Heart Failure POC And LOC Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Heart Failure POC And LOC Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Heart Failure POC And LOC Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Heart Failure POC And LOC Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Heart Failure POC And LOC Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By End Use

8. Asia Pacific Heart Failure POC And LOC Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Heart Failure POC And LOC Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Heart Failure POC And LOC Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Heart Failure POC And LOC Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Heart Failure POC And LOC Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Heart Failure POC And LOC Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Heart Failure POC And LOC Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Heart Failure POC And LOC Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Heart Failure POC And LOC Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Heart Failure POC And LOC Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By End Use

10. South America Heart Failure POC And LOC Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Heart Failure POC And LOC Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Heart Failure POC And LOC Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Heart Failure POC And LOC Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Heart Failure POC And LOC Devices Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Siemens Healthineers AG
• 15.3. Danaher Corp
• 15.4. Instrumentation Laboratory Co
• 15.5. F Hoffmann-La Roche AG
• 15.6. bioMerieux S.A.
• 15.7. Abaxis Inc
• 15.8. Quidel Corp
• 15.9. Jant Pharmacal Corp
• 15.10. Trinity Biotech plc

16. Strategic Recommendations

17. About Us & Disclaimer